Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
61 hedge funds and large institutions have $88.9M invested in Stemline Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 8 closing their positions.
0% more funds holding
Funds holding: 61 → 61 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
23% less capital invested
Capital invested by funds: $116M → $88.9M (-$27.3M)
71% less call options, than puts
Call options by funds: $70K | Put options by funds: $244K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.09M |
| 2 |
VM
VHCP Management
New York
|
+$874K |
| 3 |
State Street
Boston,
Massachusetts
|
+$424K |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$281K |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$246K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$7.27M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.35M |
| 3 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$1.94M |
| 4 |
QF
QVT Financial
New York
|
-$1.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$477K |
STML Hedge Fund Activity: Q3 2014 in Review
61 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2014, worth a combined $88.9M — down 23% from $116M a quarter earlier.
Fund positioning in STML was balanced in Q3 2014: 8 funds opened new positions, 8 closed out, 19 added to existing stakes and 20 trimmed.
The largest buyer was TFS Capital, adding an estimated $1.09M. The largest seller was Janus Henderson Investors US, exiting entirely with an estimated $7.27M sold.
- 61 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $88.9M of Stemline Therapeutics, Inc. stock for Q3 2014, down 23% quarter-over-quarter.
- 8 funds opened new Stemline Therapeutics, Inc. positions in Q3 2014 and 8 closed out, a net change of 0 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q3 2014 was TFS Capital, an estimated $1.09M added.
- The largest Stemline Therapeutics, Inc. seller in Q3 2014 was Janus Henderson Investors US, an estimated $7.27M sold.
Based on aggregated 13F filings for Q3 2014.